{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:47:40Z","timestamp":1791895660540,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.schres.2026.08.030","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:29:25Z","timestamp":1788496165000},"page":"393-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term safety and tolerability of lumateperone 42\u00a0mg in patients with stable symptoms of schizophrenia: Results from a 1-year open-label study"],"prefix":"10.1016","volume":"297","author":[{"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Durgam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Kozauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie R.","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2026.08.030_bb0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12888-018-1856-y","article-title":"Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: A survey of patients living with schizophrenia","volume":"18","author":"Achtyes","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2026.08.030_bb0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.08.030_bb0015","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"5","key":"10.1016\/j.schres.2026.08.030_bb0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.08.030_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-6-105","article-title":"Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation","volume":"6","author":"Briggs","year":"2008","journal-title":"Health Qual. Life Outcomes"},{"issue":"4","key":"10.1016\/j.schres.2026.08.030_bb0030","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/schbul\/sbac041","article-title":"Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis","volume":"48","author":"Ceraso","year":"2022","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2026.08.030_bb0035","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2026.08.030_bb0040","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40263-025-01206-3","article-title":"Strategies for switching between oral postsynaptic antidopaminergic antipsychotics in patients with schizophrenia: a systematic review","volume":"39","author":"Correll","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2026.08.030_bb0045","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.schres.2026.08.030_bb0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1017\/S1092852915000917","article-title":"Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study","volume":"21","author":"Correll","year":"2016","journal-title":"CNS Spectr."},{"issue":"2","key":"10.1016\/j.schres.2026.08.030_bb0055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.08.030_bb0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2026.08.030_bb0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.psychres.2019.02.021","article-title":"Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study","volume":"274","author":"Correll","year":"2019","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.schres.2026.08.030_bb0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2026.08.030_bb0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2020.12.006","article-title":"Safety and tolerability of lumateperone 42 mg: an open-label antipsychotic switch study in outpatients with stable schizophrenia","volume":"228","author":"Correll","year":"2021","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2026.08.030_bb0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.08.030_bb0085","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24r15316","article-title":"The economic impact of cognitive impairment and negative symptoms in schizophrenia: a targeted literature review with a focus on outcomes relevant to health care decision-makers in the United States","volume":"85","author":"Correll","year":"2024","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.08.030_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S1092852917000220","article-title":"Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study","volume":"23","author":"Cutler","year":"2018","journal-title":"CNS Spectr."},{"issue":"6","key":"10.1016\/j.schres.2026.08.030_bb0095","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.schres.2026.08.030_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.08.030_bb0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-016-4450-3","article-title":"Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study","volume":"234","author":"Durgam","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"issue":"32","key":"10.1016\/j.schres.2026.08.030_bb0110","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.schres.2026.08.030_bb0115","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ijnp\/pyy002","article-title":"A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia","volume":"21","author":"Forbes","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2026.08.030_bb0120","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2026.08.030_bb0125","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/schbul\/sbx155","article-title":"Selective attention, working memory, and executive function as potential independent sources of cognitive dysfunction in schizophrenia","volume":"44","author":"Gold","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2026.08.030_bb0130","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1192\/bjp.bp.116.190520","article-title":"Treatment of depression in schizophrenia: systematic review and meta-analysis","volume":"211","author":"Gregory","year":"2017","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.08.030_bb0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41537-023-00356-x","article-title":"Influencing factors of medication adherence in schizophrenic patients: a meta-analysis","volume":"9","author":"Guo","year":"2023","journal-title":"Schizophrenia"},{"key":"10.1016\/j.schres.2026.08.030_bb0140","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"9","key":"10.1016\/j.schres.2026.08.030_bb0145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S2215-0366(25)00162-2","article-title":"Holistic prevention and management of physical health side-effects of psychotropic medication: second report of the Lancet Psychiatry Physical Health Commission","volume":"12","author":"Halstead","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"10202","key":"10.1016\/j.schres.2026.08.030_bb0150","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2026.08.030_bb0155","series-title":"Caplyta","author":"Intra-Cellular Therapies Inc.","year":"2025"},{"issue":"6","key":"10.1016\/j.schres.2026.08.030_bb0160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/pcn.12654","article-title":"Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label study","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2026.08.030_bb0165","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08r04210","article-title":"Akathisia: an updated review focusing on second-generation antipsychotics","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2026.08.030_bb0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","article-title":"Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia","volume":"174","author":"Kane","year":"2016","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2026.08.030_bb0175","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/YIC.0000000000000371","article-title":"Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials","volume":"36","author":"Kane","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2026.08.030_bb0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2026.08.030_bb0185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2019.052","article-title":"Stopping and switching antipsychotic drugs","volume":"42","author":"Keks","year":"2019","journal-title":"Aust. Prescr."},{"issue":"10","key":"10.1016\/j.schres.2026.08.030_bb0190","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","article-title":"Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application","volume":"181","author":"Leucht","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.08.030_bb0195","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jad.2020.04.056","article-title":"Prevalence of comorbid depression in schizophrenia: a meta-analysis of observational studies","volume":"273","author":"Li","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.schres.2026.08.030_bb0200","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2026.08.030_bb0205","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40263-025-01218-z","article-title":"Antipsychotic-related prolactin changes: a systematic review and dose\u2013response meta-analysis","volume":"39","author":"Lin","year":"2025","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.schres.2026.08.030_bb0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12888-017-1213-6","article-title":"Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications","volume":"17","author":"Llorca","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"18","key":"10.1016\/j.schres.2026.08.030_bb0215","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.schres.2026.08.030_bb0220","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2026.08.030_bb0225","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/YIC.0000000000000091","article-title":"Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia","volume":"30","author":"Meyer","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2026.08.030_bb0230","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m14881","article-title":"Effect of lurasidone on social functioning in schizophrenia","volume":"85","author":"Miura","year":"2024","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2026.08.030_bb0235","first-page":"323","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.schres.2026.08.030_bb0240","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S2215-0366(25)00025-2","article-title":"The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophrenia","volume":"12","author":"Nomura","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.08.030_bb0245","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1185\/03007990802611919","article-title":"Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia","volume":"25","author":"Patrick","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"issue":"12","key":"10.1016\/j.schres.2026.08.030_bb0250","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2026.08.030_bb0255","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/schbul\/sbab063","article-title":"Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study","volume":"47","author":"Rubio","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.08.030_bb0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"3","key":"10.1016\/j.schres.2026.08.030_bb0265","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2026.08.030_bb0270","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.schres.2026.08.030_bb0275","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.euroneuro.2024.07.009","article-title":"Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: a subanalysis of a systematic review and meta-analysis with meta-regression of moderators","volume":"88","author":"Solmi","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.08.030_bb0280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euroneuro.2024.11.001","article-title":"Sex-stratified mortality estimates in people with schizophrenia: a systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia","volume":"91","author":"Solmi","year":"2025","journal-title":"Opean Neuropsychopharmacol."},{"issue":"18","key":"10.1016\/j.schres.2026.08.030_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17186700","article-title":"Risk factors of metabolic syndrome in community-dwelling people with schizophrenia","volume":"17","author":"Sun","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"2","key":"10.1016\/j.schres.2026.08.030_bb0290","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11892-015-0704-4","article-title":"Diabetes and schizophrenia","volume":"16","author":"Suvisaari","year":"2016","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.schres.2026.08.030_bb0295","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.06.009","article-title":"Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: a dopamine D1 receptor dependent mechanism","volume":"62","author":"Titulaer","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.08.030_bb0300","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 Well-Being Index: a systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychother. Psychosom."},{"issue":"3","key":"10.1016\/j.schres.2026.08.030_bb0305","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.08.030_bb0310","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.08.030_bb0315","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia","volume":"44","author":"Vanover","year":"2019","journal-title":"Neuropsychopharmacology"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426002811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426002811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:03:24Z","timestamp":1791893004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":63,"alternative-id":["S0920996426002811"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.08.030","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and tolerability of lumateperone 42\u00a0mg in patients with stable symptoms of schizophrenia: Results from a 1-year open-label study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}